Jaguar health reports second quarter 2024 financial results

The combined net q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net q1 2024 revenue of $2.35 million and 2.0% versus net q2 2023 revenue of $2.67 million company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 ontarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (ctd) in support of fda discussion; jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 results jaguar planning to begin commercial launch in october 2024 for gelclair ®, the company's third prescription product import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in abu dhabi in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (mvid) and short bowel syndrome (sbs) with intestinal failure reminder: jaguar to host investor webcast tuesday, august 13th at 8:30 a.m. eastern regarding q2 2024 financials and company updates; click here to register for webcast san francisco, ca / accesswire / august 13, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today reported its consolidated second-quarter 2024 financial results and provided company updates.
JAGX Ratings Summary
JAGX Quant Ranking